Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Johnston, Belfast
James Johnston, Belfast GB
| Patent application number | Description | Published |
|---|---|---|
| 20090208446 | DUB3 as a Cancer Therapy Target - Described is a method of modulating the activation of a Rho, Arf, Rab, Ran or Rap family protein, said method comprising administering to said sample a USP-17 modulator, for example an inhibitor of expression or activity of DUB-3. The invention enables the use of USP-17 modulators in the treatment of metastatic cancer and other conditions. | 08-20-2009 |
| 20090269360 | THERAPY - The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumour cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent. | 10-29-2009 |
| 20100086551 | ANTIBODY AND USES THEREOF - A method of inhibiting angiogenesis in a group of cells, a tissue or an organ includes administering an antibody molecule or nucleic acid encoding an antibody molecule to the cells, tissue or organ, wherein the antibody molecule specifically binds cathepsin S, but does not inhibit proteolytic activity of cathepsin S. | 04-08-2010 |
| 20100111965 | COMBINATION THERAPY - The invention provides a method of treating neoplastic disease in a subject, said method comprising the simultaneous, sequential or separate, administration to said subject of an effective amount of (i) an inhibitor of a first EGF, e.g. HB-EGF and (ii) an inhibitor of a second EGF, e.g. AREG. Also described are novel synergistic combinations of EGF inhibitors with topoisomerase inhibitors which attenuate tumour cell growth. Further described are novel anti AREG antibodies. | 05-06-2010 |
| 20110150886 | ANTI-AREG/HB-EGF ANTIBODIES AND TREATMENT - Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis. | 06-23-2011 |
James A. Johnston, Belfast GB
| Patent application number | Description | Published |
|---|---|---|
| 20090053258 | Assays for diagnosis of tuberculosis and uses thereof - The invention relates to the identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis and the discrimination between infected animals and animals previously exposed to vaccines. | 02-26-2009 |
| 20110020404 | DIAGNOSTIC METHOD AND KIT - The invention relates to methods for diagnosis of tuberculosis in an animal, the methods comprising determining the presence or absence of, or an immune response to a group of antigens comprising (i) the group consisting of Rv3616 antigen, MPB70 antigen, MPB83 antigen, and ESAT 6 antigen; or (ii) at least seven of the antigens of the group consisting of Rv3616 antigen, MPB70 antigen, MPB83 antigen, ESAT 6 antigen, CFP10 antigen, α crystalline 2 antigen, PE35 antigen, and PPE68 antigen. Also provided is a method for the diagnosis of the presence of tuberculosis in a reservoir animal e.g. a badger, said method comprising determining the presence or absence of, or an immune response to Rv3616 antigen, MPB70 antigen, and MPB83 antigen. Kits for carrying out the methods are also provided. | 01-27-2011 |
James A. Johnston, Belfast IE
| Patent application number | Description | Published |
|---|---|---|
| 20110177526 | JANUS FAMILY KINASES AND IDENTIFICATION OF IMMUNE MODULATORS - An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing. | 07-21-2011 |
Jim Johnston, Belfast IE
| Patent application number | Description | Published |
|---|---|---|
| 20090317405 | ANTIBODY AND USES THEREOF - Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis. | 12-24-2009 |
Jim Johnston, Belfast GB
| Patent application number | Description | Published |
|---|---|---|
| 20090068198 | Antibody and Uses Thereof - Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis. | 03-12-2009 |
| 20100104554 | PEPTIDE AND USES THEREOF - A method of inhibiting activity of a cathepsin L-like protease in cells or tissue and the use of the method in the treatment of disease such as cancer and inflammatory diseases is described. The method comprises administration of a cathepsin propeptide or a nucleic acid encoding a cathepsin propeptide. In particular embodiments, the propeptide is a Cathepsin S propeptide. Further, the use of propeptides having an Fc portion is described. | 04-29-2010 |
Patrick Johnston, Belfast GB
| Patent application number | Description | Published |
|---|---|---|
| 20090047221 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA - There is described compounds for use in therapy, said compounds being defined by Formula (1): There is also described an anti-proliferative composition comprising one or more compounds according to Formula (1), and a method of treatment of neoplasia comprising the administration of such a compound or composition. | 02-19-2009 |
Patrick Gerard Johnston, Belfast GB
| Patent application number | Description | Published |
|---|---|---|
| 20090312395 | Assay - RAN and RAN Binding Protein 1 have been determined to be markers of invasive and metastatic potential of a tumour cell. There is described methods and kits for the detection of the level of RAN and RAN Binding Protein 1 and the use thereof. | 12-17-2009 |